Summary of Ardelyx Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $118 million, a 31% increase year-over-year, marking the highest quarterly revenue in company history.

IBSRELA Revenue: $86.2 million, up 33% year-over-year.

XPHOZAH Revenue: $31.9 million, a 27% increase year-over-year.

Net Loss: $16.7 million, improved from a net loss of $19.1 million in Q2 2025.

Cash Position: $281.8 million in cash, cash equivalents, and short-term investments.

OPEX Guidance: Revised to below $500 million for 2026.

2Strategic Updates and Business Highlights

IBSRELA and XPHOZAH: Both products are experiencing strong demand, but IBSRELA faces payer hurdles affecting new patient starts.

Field Reimbursement Team: Expanded to address access issues, with plans to enhance patient support and prescription fulfillment.

Patient Engagement Initiatives: New direct-to-consumer activities planned to boost brand awareness.

Pipeline Development: Continued investment in tenapanor and other business development activities to expand the pipeline.

3Forward Guidance and Outlook

Revised IBSRELA Guidance: Lowered to $350 million - $370 million for 2026, still representing over 30% growth at the midpoint.

XPHOZAH Revenue Guidance: Reiterated at $110 million - $120 million for 2026.

Path to Profitability: Projected for 2027, with expectations of narrowing losses and sustainable revenue growth.

4Bad News, Challenges, or Points of Concern

Payer Hurdles: Increased step edits and stringent prior authorizations are slowing new patient starts for IBSRELA, impacting access.

Market Dynamics: The competitive landscape for IBS-C treatments is becoming more challenging, with payer pushback noted across the category.

Litigation Outcome: The company decided to cease further litigation against CMS regarding oral-only phosphate-lowering drugs remaining in the bundle, indicating regulatory challenges.

5Notable Q&A Insights

Demand Metrics: Strong refill rates and total prescriptions for IBSRELA, but access challenges are hindering new patient starts.

Payer Dynamics: The company is experiencing heightened scrutiny from payers, leading to more stringent access criteria.

Business Development: Ardelyx is actively seeking new assets despite a competitive M&A landscape, with a focus on enhancing their pipeline.

Profitability Timeline: Management remains confident in achieving profitability in 2027, with a narrowing loss trend observed in recent quarters. Overall, while Ardelyx reported strong financial results and maintains a positive outlook for its products, it faces significant challenges related to payer access and market dynamics that could impact growth.